ion torrent



Oncomine Dx Target Test—FDA approved

Ask your pathologist about Oncomine Dx Target Test

A new paradigm in testing for targeted therapies in NSCLC

This test is now reimbursed by Medicare and the top 40 commercial payers, covering over 200 million US lives.

The Ion Torrent™ Oncomine™ Dx Target Test is the first targeted next-generation sequencing (NGS) *in vitro* diagnostic test for non–small cell lung cancer (NSCLC), simultaneously delivering multiple biomarker results for multiple targeted therapies from one sample within 4 days.

Did you know:

- Many biopsy samples are so small that they cannot be analyzed by some NGS tests, especially panels containing hundreds of genes, leading to tissue exhaustion
- It can take several weeks to get results with alternative NGS tests, potentially delaying treatment decision

Choosing the right NGS test can make a difference for your patient

The Oncomine Dx Target Test is an FDA-approved NGS CDx test that can:

- Identify patients for multiple therapies—one test indicated as a companion diagnostic (CDx) device to aid in selecting NSCLC patients for treatment with targeted therapies
- Accept small samples (10 ng DNA and RNA), for more patients to potentially access targeted therapies
- Generate results in a laboratory within four days, enabling faster treatment decisions



Cancer type	Gene	Targeted therapies
NSCLC	*BRAF*	TAFINLAR® (dabrafenib) in combination with MEKINIST® (trametinib)
	EGFR	IRESSA® (gefitinib)
	RET	GAVRETO™ (pralsetinib)
	ROS1	XALKORI® (crizotinib)

Figure 1. List of genes for therapeutic use.

ThermoFisher SCIENTIFIC

For *In Vitro* Diagnostic Use.

ion torrent



Figure 2. Complete gene list. * The test reports fusion/translocation variants for *ROS1* and *RET* only. The test only reports *ALK* and *MET* mutations. ** Performance for the additional gene target variants has been validated based on a representative method.

Oncomine Dx Target Test—performance

Concordance with FDA approved or validated reference methods based on FISH, PCR, or NGS was established for all CDx biomarkers: overall percent agreement (OPA) of 100% for *BRAF*, 99% for *EGFR*, 100% for *ROS1*, and 92% for *RET*.

Oncomine Dx Target Test—report

NSCLC results for sequence variations for therapeutic use (for illustrative purposes only; *EGFR*, *BRAF*, *ROS1, and RET are m*utually exclusive)

DNA sequence variants						
Gene	Display name	Amino acid change	Nucleotide change	Test result	Hotspot ID	Associated therapy
EGFR	*EGFR* L858R	p.Leu858Arg	c.2573T>G	POSITIVE	COSM6224	IRESSA® (gefitinib)
BRAF	*BRAF* V600E	p.Val600Glu	c.1799T>A	POSITIVE	COSM476	TAFINLAR® + MEKINIST® (dabrafenib in combination with trametinib)
Gene fusions (RNA)						
Gene	Display name			Test result		Associated therapy
ROS1	*ROS1* fusions			POSITIVE		XALKORI® (crizotinib)
RET	*RET* fusions			POSITIVE		GAVRETO™ (pralsetinib)

Figure 3. Example of Oncomine Dx Target Test report format. The report includes a section with results of the validated biomarkers and information about relevant treatment indication, as well as a separate section with the other biomarkers not validated for treatment selection (not shown).

If your pathology laboratory does not perform the Oncomine Dx Target Test, you can send samples to one of these reference laboratories.

Reference lab	Telephone number	Website
Integrated Oncology (a division of LabCorp)	800-447-5816	**integratedoncology.com**
Quest Diagnostics, Inc.	866-697-8378	**questdiagnostics.com**
NeoGenomics Laboratories, Inc.	866-776-5907	**neogenomics.com**
Phenopath, a Quest Diagnostics Company	888-927-4366	**phenopath.com**

Find out more at **thermofisher.com/oncomine-dxtarget**

ThermoFisher SCIENTIFIC

For *In Vitro* Diagnostic Use. The content provided herein may relate to products that have not been officially released and is subject to change without notice. © 2017, 2020 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. XALKORI is a registered trademark of Pfizer Inc. TAFINLAR and MEKINIST are registered trademarks of Novartis. IRESSA is a registered trademark of AstraZeneca, GAVRETO is a trademark of Blueprint Medicines Corporation. **COL112811 1020 EXT0002584**